Adjuvant therapy of pancreatic cancer. Academic Article uri icon

Overview

abstract

  • Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.

publication date

  • July 10, 2012

Research

keywords

  • Pancreatic Neoplasms

Identity

Scopus Document Identifier

  • 84864497372

Digital Object Identifier (DOI)

  • 10.6092/1590-8577/935

PubMed ID

  • 22797387

Additional Document Info

volume

  • 13

issue

  • 4